Compare · DFTX vs ISPR
DFTX vs ISPR
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Ispire Technology Inc. (ISPR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and ISPR operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $5.34B, about 63.3x ISPR ($84.4M).
- DFTX has been more active in the news (12 items in the past 4 weeks vs 5 for ISPR).
- DFTX has more recent analyst coverage (7 ratings vs 2 for ISPR).
- Company
- Definium Therapeutics Inc.
- Ispire Technology Inc.
- Price
- -
- -
- Market cap
- $5.34B
- $84.4M
- 1M return
- -
- +0.00%
- 1Y return
- -
- -53.92%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- News (4w)
- 12
- 5
- Recent ratings
- 7
- 2
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 30% to 271,987 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 34% to 1,473,246 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 19% to 383,071 units (SEC Form 4)
Latest ISPR
- Ispire Technology Inc. Appoints Steven Przybyla as President
- Ispire Technology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Cox Brent was granted 53,555 shares, increasing direct ownership by 62% to 139,863 units (SEC Form 4)
- Director Burch Christopher Robert was granted 45,760 shares, increasing direct ownership by 59% to 122,944 units (SEC Form 4)
- Director Fargis John was granted 45,760 shares, increasing direct ownership by 61% to 120,385 units (SEC Form 4)
- BTIG Research initiated coverage on Ispire Technology with a new price target
- SEC Form 8-K filed by Ispire Technology Inc.
- Ispire Technology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form DEFA14A filed by Ispire Technology Inc.
- SEC Form DEF 14A filed by Ispire Technology Inc.